Vytorin Gets Medical Group Support, Congressional Query On ENHANCE
Executive Summary
Merck/Schering-Plough's Vytorin has drawn support from major medical groups as it faces a new Congressional inquiry and possible legal action in the wake of unfavorable study results from the much-anticipated ENHANCE trial
You may also be interested in...
Vytorin Won’t Be ENHANCEd By Part D In 2009: Formulary Review
Three of the leading Medicare Part D sponsors will not cover Merck/Schering-Plough's Vytorin in their stand-alone drug plans in 2009, and much of the blame can probably be laid on the disappointing results of the ENHANCE study earlier this year
Vytorin Won’t Be ENHANCEd By Part D In 2009: Formulary Review
Three of the leading Medicare Part D sponsors will not cover Merck/Schering-Plough's Vytorin in their stand-alone drug plans in 2009, and much of the blame can probably be laid on the disappointing results of the ENHANCE study earlier this year
Rep. Dingell’s Prescription For DTC Offered To Pharma Panel At Hearing
House Energy and Commerce Committee Chairman John Dingell, D-Mich., outlined several precepts for enhancing direct-to-consumer drug advertising at a May 8 hearing by the Energy and Commerce Oversight and Investigations Subcommittee